Compare Amer Sports Inc (AS) vs DexCom, Inc. (DXCM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amer Sports Inc vs DexCom, Inc. — how do they compare? Amer Sports Inc trades at $34.75 (market cap $20.25B), while DexCom, Inc. trades at $75 (market cap $28.93B). The key difference: DexCom, Inc. is the larger of the two by market cap, and DexCom, Inc. is trading nearer its 52-week high, Amer Sports Inc nearer its low. Which is the better fit depends on your goals.
| AS | DXCM | |
|---|---|---|
Market Cap | $20.25B | $28.93B |
Sector | Technology | Health |
52-Week High | $41.96 | $89.53 |
52-Week Low | $29.54 | $54.84 |
Enterprise Value | $20.56B | $27.89B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amer Sports (AS) trades at $34.80, up 2.75% today, with strong Q1 2026 earnings beating estimates and raised full-year guidance. Technicals show a bearish trend near key support at $33, while fundamentals reflect robust revenue growth of 32% year-over-year and a 58.23% gross margin. Analyst sentiment is overwhelmingly positive with 12 buy ratings and a $56 consensus target, indicating 61% upside potential from current levels.
The outlook remains favorable given earnings momentum and raised guidance, but risks include reliance on Arc'teryx brand sustainability and competitive pressures. Valuation metrics like a P/E of 43.49 suggest premium pricing, requiring continued execution to justify upside. Net positive cash flow and institutional support provide stability amid technical weakness.
DXCM trades at $74.96, up 2.66% today, with strong technical momentum as price approaches resistance near $76. The company demonstrates robust fundamentals with revenue growth from $2.9B in 2022 to $4.7B in 2025 and expanding net margins to 17.93%. Recent FDA clearance for pediatric Stelo CGM and positive CONNECT trial results support growth in the non-insulin diabetes market.
Outlook remains positive with 80% analyst buy ratings and $83.78 consensus target, though risks include GLP-1 drug competition and execution in expanding beyond insulin-dependent patients. Earnings beat expectations in three consecutive quarters, with Q2 2026 results anticipated July 30, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amer Sports Inc
Amer Sports is a global group of iconic sports and outdoor brands, including Arc'teryx, Salomon, Wilson, and Atomic. It designs and manufactures high-quality equipment, apparel, and footwear for athletes worldwide.
Read more on AS →About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →
